{
  "id": "602745c51cb411341a0000de",
  "type": "summary",
  "question": "Describe the mechanism of action of Lisocabtagene maraleucel.",
  "ideal_answer": "Lisocabtagene maraleucel is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31899702",
    "http://www.ncbi.nlm.nih.gov/pubmed/32611216",
    "http://www.ncbi.nlm.nih.gov/pubmed/32670869",
    "http://www.ncbi.nlm.nih.gov/pubmed/32888407",
    "http://www.ncbi.nlm.nih.gov/pubmed/31677848",
    "http://www.ncbi.nlm.nih.gov/pubmed/31099671",
    "http://www.ncbi.nlm.nih.gov/pubmed/31648957",
    "http://www.ncbi.nlm.nih.gov/pubmed/32740094"
  ],
  "snippets": [
    {
      "text": "Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31899702",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for patients with CD19 B-cell malignancies. Combination strategies that improve CAR T-cell potency, limit tumor environment-mediated immune dysfunction, and directly reduce tumor burden may increase the potential for durable clinical benefit of CAR T-cell therapy. Lisocabtagene maraleucel (liso-cel) is a product therapy candidate being tested in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31899702",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two second-generation anti-CD19 CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel, have been approved for use in patients, and the approval of a third product, lisocabtagene maraleucel, is expected in 2020.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32670869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, three CAR T-cell products are approved or soon to be approved: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32611216",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Since the first report of CD19-directed CAR-T-cell therapy in 2010, three constructs have been tested in large phase I/II trials and resulted in 30-40% durable responses. This has led to Food and Drug Administration and European Medicines Agency approval for axicabtagene ciloleucel and tisagenlecleucel and filing of the biologics license application for lisocabtagene maraleucel. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32740094",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32888407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32888407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we provide a thorough review on the use of the anti-CD19 CAR T-cell products axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel in patients with indolent or aggressive B-cell lymphoma or with chronic lymphocytic leukemia, and present novel CAR T cell-based approaches currently under investigation in these disease settings.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32670869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell p",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32888407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "hree anti-CD19 CAR T-cells are currently Food and Drug Administration and European Medicines Agency approved or in advanced-stage development: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. A",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31677848",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32888407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-c",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32888407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A third anti CD19 CAR-T cell, lisocabtagene ciloleucel is currently being evaluated in large clinical trials and may also be United States Food and Drug Administration-approved soon.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31648957",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three anti-CD19 CAR T cells for aggressive B-cell lymphoma (axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene ciloleucel) are either U.S. Food and Drug Administration approved or in late-stage development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31099671",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}